(Q36972988)

17 August 2017

1 reference

title

Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders (English)

1 reference

17 August 2017

1 reference

Chrisp P

1

1 reference

PubMed ID

1794035

17 August 2017

Sorkin EM

series ordinal

2

1 reference

17 August 2017

1 November 1991

1 reference

17 August 2017

1 reference

17 August 2017

1

1 reference

17 August 2017

6

1 reference

17 August 2017

487-509

1 reference

https://scigraph.springernature.com/pub.10.2165/00002512-199101060-00008

17 August 2017

0 references

cites work

GnRH agonists and antagonists. Current clinical status

1 reference

12 December 2020

Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate.

1 reference

12 December 2020

Regulation of alpha and rat luteinizing hormone-beta messenger ribonucleic acids during gonadotropin-releasing hormone agonist treatment in vivo in the male rat.

1 reference

12 December 2020

Leuprorelin acetate depot in advanced prostatic cancer: a phase II multicentre trial

1 reference

12 December 2020

Zoladex and flutamide versus bilateral orchiectomy. A randomized phase III EORTC 30853 study. The EORTC GU Group

1 reference

12 December 2020

3.75 and 7.5 mg leuprorelin acetate depot in the treatment of advanced prostatic cancer: preliminary report. German Leuprorelin Study Group

1 reference

12 December 2020

Preliminary clinical evaluation of leuprorelin acetate depot injection in France, in the management of prostatic cancer

1 reference

12 December 2020

Relative effectiveness of alternative androgen withdrawal therapies in initiating regression of rat prostate

1 reference

12 December 2020

Controlled release of LHRH agonist, leuprolide acetate, from microcapsules: serum drug level profiles and pharmacological effects in animals

1 reference

12 December 2020

Testicular histology following chronic gonadotropin-releasing hormone agonist treatment

1 reference

12 December 2020

Leuprolide versus diethylstilbestrol for metastatic prostate cancer

1 reference

12 December 2020

Testicular histology after prolonged treatment with a gonadotropin-releasing hormone analogue

1 reference

12 December 2020

Carcinoma of the prostate: a review

1 reference

12 December 2020

Nafarelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical potential in sex hormone-related conditions

1 reference

12 December 2020

[Clinical and endocrinological studies of the luteinizing hormone-releasing hormone analogue therapy in prostatic cancer patients]

1 reference

12 December 2020

Evaluation of synthetic agonist analogue of gonadotropin-releasing hormone (leuprolide) on testicular androgen production in patients with carcinoma of prostate

1 reference

12 December 2020

One-month release injectable microcapsules of a luteinizing hormone-releasing hormone agonist (leuprolide acetate) for treating experimental endometriosis in rats

1 reference

12 December 2020

Controlled-release of leuprolide acetate from polylactic acid or copoly(lactic/glycolic) acid microcapsules: influence of molecular weight and copolymer ratio of polymer

1 reference

12 December 2020

Des lead-in to use of luteinizing hormone releasing hormone analogs in treatment of metastatic carcinoma of prostate

1 reference

12 December 2020

Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today's therapy of choice

1 reference

12 December 2020

Leuprolide: a review of its effects in animals and man

1 reference

12 December 2020

The biology of gonadotropin-releasing hormone and its analogs

1 reference

12 December 2020

Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions

1 reference

12 December 2020

Leuprolide therapy for prostate cancer. An association with scintigraphic "flare" on bone scan

1 reference

12 December 2020

Endocrine treatment of benign prostatichypertrophy: Current concepts

1 reference

12 December 2020

Leuprorelin acetate depot: results of a multicentre Japanese trial. TAP-144-SR Study Group

1 reference

12 December 2020

Pharmaceutical manipulation of leuprorelin acetate to improve clinical performance

1 reference

12 December 2020

Androgen suppression by a gonadotropin releasing hormone analogue in patients with metastatic carcinoma of the prostate

1 reference

12 December 2020

NIH conference. Therapeutic applications of luteinizing-hormone-releasing hormone and its analogs

1 reference

12 December 2020

Leuprolide acetate lowers circulating bioactive luteinizing hormone and testosterone concentrations during ovarian stimulation for oocyte retrieval.

1 reference

12 December 2020

Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients

1 reference

12 December 2020

Effect of the intranasal administration of LHRH superanalogue on endogenous LHRH in humans

1 reference

12 December 2020

The treatment of metastatic prostatic cancer with a potent luteinizing hormone releasing hormone analogue

1 reference

12 December 2020

Gonadotropin-releasing hormone analogs and prostatic cancer

1 reference

12 December 2020

Effect of very high dose D-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer

1 reference

12 December 2020

In vivo release profiles of leuprolide acetate from microcapsules prepared with polylactic acids or copoly(lactic/glycolic) acids and in vivo degradation of these polymers

1 reference

12 December 2020

Effects of the gonadotropin-releasing hormone agonist [D-leu6, desgly-NH2(10), proethylamide9]-GnRH (leuprolide) on R3327-G rat prostatic tumor growth

1 reference

12 December 2020

Symptom status and quality of life following prostatectomy.

1 reference

12 December 2020

Long-term suppression of luteinizing hormone, follicle-stimulating hormone and testosterone by daily administration of leuprolide

1 reference

12 December 2020

In vitro effects of diethylstilboestrol and the LHRH analogue leuprolide on natural killer cell activity

1 reference

12 December 2020

Management of urinary retention due to benign prostatic hyperplasia using luteinizing hormone-releasing hormone agonist

1 reference

12 December 2020

Clinical phase III study on TAP-144-SR, an LH-RH agonist depot formulation, in patients with prostatic cancer

1 reference

12 December 2020

Blood and urine clearance of luteinizing hormone releasing hormone in man measured by radioimmunoassay

1 reference

12 December 2020

Counteractive effects of agonistic and antagonistic gonadotropin-releasing hormone analogs on spermatogenesis: sites of action

1 reference

12 December 2020

Clinical efficacy and safety of a new leuprorelin acetate depot formulation in patients with advanced prostatic cancer

1 reference

12 December 2020

Leuprolide with and without flutamide in advanced prostate cancer

1 reference

12 December 2020

Treatment of prostate cancer with gonadotropin-releasing hormone agonists

1 reference

12 December 2020

A comparison of a powerful luteinizing hormone releasing hormone analogue agonist and estrogen in the treatment of advanced prostatic cancer

1 reference

12 December 2020

[Clinical phase I and phase II study on a sustained release formulation of leuprorelin acetate (TAP-144-SR), an LH-RH agonist, in patients with prostatic carcinoma. Collaborative++ Studies on Prostatic Carcinoma by the Study Group for TAP-144-SR.]

1 reference

12 December 2020

[LH-RH treatment of patients with prostatic cancer by subcutaneous injection, non-biodegradable and biodegradable slow delivery system and intranasal spray application]

1 reference

12 December 2020

Pharmaceutical aspects. Nasal and depot formulations of leuprolide

1 reference

12 December 2020

Combined androgen blockade

1 reference

12 December 2020

Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluation

1 reference

12 December 2020

Effect of long-acting gonadotropin-releasing hormone analog (leuprolide) therapy on prostatic size and symptoms in 15 men with benign prostatic hypertrophy

1 reference

12 December 2020

Endocrine and clinical effects of leuprolide in prostatic cancer

1 reference

12 December 2020

Gonadotropin hormone-releasing hormone analogues: a new therapeutic approach for prostatic carcinoma

1 reference

12 December 2020

[Testicular endocrine function in patients with prostatic cancer receiving medical castration by long-term administration of LH-RH agonists]

1 reference

12 December 2020

Effect of leuprolide on growth of rat prostatic tumor (R 3327) and weight of male accessory sex organs

1 reference

12 December 2020

Hypophysial Responses to Continuous and Intermittent Delivery of Hypothalamic Gonadotropin-Releasing Hormone

1 reference

12 December 2020

Efficacy of (D-Leu6)-des Gly-NH2 10-LHRH ethylamide against prostatic cancer

1 reference

12 December 2020

High-performance liquid chromatography followed by radioimmunoassay for the determination of a luteinizing hormone-releasing hormone analogue, leuprorelin, and its metabolite

1 reference

12 December 2020

Carcinoma of the prostate. Treating disease that has metastasized

1 reference

12 December 2020

Zoladex and flutamide versus orchiectomy in the treatment of advanced prostatic cancer. A combined analysis of two European studies, EORTC 30853 and DAPROCA 86

1 reference

12 December 2020

Drug Therapy of Prostatic Cancer

1 reference

12 December 2020

Pathologic changes associated with androgen deprivation therapy for prostate cancer

1 reference

12 December 2020

Antifertility effects of LHRH agonists in the male rat and inhibition of testicular steroidogenesis in man

1 reference

12 December 2020

An approach to the elucidation of metabolic breakdown products of the luteinizing hormone-releasing hormone

1 reference

12 December 2020

Treatment of prostate cancer

1 reference

12 December 2020

Estrogen in patients with prostatic cancer. An assessment of the risks and benefits

1 reference

12 December 2020

Gonadotropin-releasing hormone and its analogues

1 reference

12 December 2020

Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile

1 reference

12 December 2020

Long term effects of administration of a gonadotropin-releasing hormone superagonist analog in men with prostatic carcinoma

1 reference

12 December 2020

Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostate

1 reference

12 December 2020

Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. Zoladex Prostate Study Group

1 reference

12 December 2020

Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. The Leuprolide Study Group

1 reference

12 December 2020

Current Concepts in the Treatment of Genitourinary Tract Disorders in the Older Individual

1 reference

12 December 2020

Effects of chronic D-Leu6, des-Gly10-gonadotropin releasing hormone ethylamide on male sex tissues

1 reference

12 December 2020

[Hormonal and clinical efficacy of (D-Leu6)-des Gly-NH2(10)-LH.RH ethylamide against prostatic cancer]

1 reference

12 December 2020

Single-dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration

1 reference

12 December 2020

Effect of a GnRH analogue (leuprolide) on benign prostatic hypertrophy

1 reference

12 December 2020

Flutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in advanced prostatic cancer

1 reference

12 December 2020

Human pharmacokinetic and pharmacodynamic profiles of leuprorelin acetate depot in prostatic cancer patients

1 reference

12 December 2020

Effect of adrenalectomy, flutamide, and leuprolide on the growth of the Dunning rat R-3327 prostatic carcinoma

1 reference

12 December 2020

The sustained release of LH X RH agonist from LH X RH agonist-polymer composite in patients with prostatic cancer

1 reference

12 December 2020

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

12 December 2020

Transdermal versus subcutaneous leuprolide: a comparison of acute pharmacodynamic effect

1 reference

12 December 2020

A radioimmunoassay for a highly active luteinizing hormone-releasing hormone analogue and relation between the serum level of the analogue and that of gonadotropin

1 reference

12 December 2020

Serum prostate-antigen levels in patients with benign prostatic hypertrophy treated with leuprolide

1 reference

12 December 2020

Leuprolide: a gonadotropin-releasing hormone analog for the palliative treatment of prostatic cancer.

1 reference

12 December 2020

10.2165/00002512-199101060-00008

Identifiers

DOI

1 reference

PubMed ID

1794035

Dimensions Publication ID

17 August 2017

0 references

1 reference

PubMed ID

1794035